Apogenix myelodysplastic syndrome therapy wins FDA orphan drug designation
Apogenix also announced the commencement of Apocept Phase I trial in MDS patients in Germany. Endpoints of the open-label study include efficacy (improvement of erythropoiesis), safety, and tolerability
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.